In 2020, the Chinese orthobiologics market size was valued at $460.7 million, with over 424,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 6% to reach $690.8 million in 2026. Throughout this medical market research, we analyzed 28 orthobiologics companies across China
In 2020, the Indian orthobiologics market size was valued at $76.2 million, with over 520,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 12.4% to reach $172.3 million in 2026. Throughout this medical market research, we analyzed 23 orthobiologics companies across India
In 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026. Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia
The European Orthopedic Biomaterials market report covers and includes the Bone Graft Substitutes Market, Orthopedic Growth Factor Market , Orthopedic Cell Therapy Market, Hyaluronic Acid Viscosupplementation Market, and the Orthopedic Cartilage Repair Market.
Overall, the U.S. Orthopedic Biomaterials market was valued at $3.7 billion in 2021. This is expected to increase over the forecast period at a CAGR of 3.6% to reach $4.7 billion. Demographic factors in the U.S. continue to be the largest driver within the orthopedic biomaterials market. This is primarily due to the growing elderly
Industry Trends A particular trend in the U.S. orthobiologics market is competitors that are seeking to penetrate high growth segments outside their traditional space by distributing existing products manufactured by other companies, rather than creating their own. This often involves partnering with a company by taking on the costs associated with regulation and market approval,
Bone morphogenetic proteins (BMPs) are growth factors that induce the formation of bone after a fracture. In nature, these proteins have a critical role during embryonic development in the formation of the skeleton. There are twenty different BMPs that have been discovered thus far, of which only two, BMP-2 and BMP-7, have been commercialized as bone graft substitutes for use in specific orthopedic procedures. The commercial versions of these products are produced by recombinant genetic engineering, which results in a recombinant human protein. The recombinant human BMP-2 (rhBMP-2) is marketed as a commercial product by Medtronic, Inc. and is called Infuse® (InductOS® in Europe), while BMP-7 has been commercialized by Stryker Inc. and is sold to Olympus under the name of OP-1®. Both molecules mediate the process of osteoblast differentiation. BMP-2 is capable of stimulating immature mesenchymal cells to form into bone, while BMP-7 has been shown to be capable of stimulating cartilage growth.
Growth factors are a group of small, soluble proteins that bind onto cell surface receptors, triggering a series of signals that regulate the bodys ability to grow, renew and heal. Due to the regenerative properties of growth factors, they have been exploited for bone healing in orthopedic applications. Since September 1, 2015, there are two main growth factor products offered in the U.S. market: INFUSE® by Medtronic and AUGMENT® by Wright Medical. Strykers OP-1 which had been sold to Olympus Biotech is no longer available as Olympus Biotech ceased sales May 31, 2014. Strykers OP-1 is a different form of bone morphogenic proteins (BMPs) that belong to a larger family of proteins called transforming growth factors.
Each of the three markets discussed in the report has a unique set of factors affecting its growth profile. In terms of the market drivers, for example, the bone graft market is seeing increasing adoption rate as newly trained surgeons are entering the workforce. The viscosupplementation market continues to bring improved products along with expanded indications. The bone stimulator market maintains a high clinical success rate and is therefore also increasing its adoption rate.